InternationalResearch and clinical trials
Setrusumab did not significantly reduce fractures in brittle bone disease in two phase 3 trials
An early result that has not yet been published in a peer-reviewed journal, or comes from a small, uncontrolled study. Treat it with caution.
Setrusumab, tested in brittle bone disease (osteogenesis imperfecta), did not reach its main goal in two large studies. The results were announced on December 29, 2025. The Orbit study included 159 patients aged 5 to 25 years. The Cosmic study included 69 children aged 2 to 7 years. The drug increased bone density but did not significantly reduce the number of fractures.
What does it mean for patients and families?
This drug is not an approved treatment. The companies are reviewing the data again, especially for children. The results have not yet been published in a peer-reviewed journal.
Source
Mereo BioPharma: Phase 3 ORBIT and COSMIC Results
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Osteogenesis imperfecta (brittle bone disease)
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.